Trial Profile
A phase Ib, open label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending oral doses of Rimeporide in patients with Duchenne Muscular Dystrophy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jul 2021
Price :
$35
*
At a glance
- Drugs Rimeporide (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Acronyms Rim4DMD
- Sponsors Merck Serono
- 16 Mar 2018 According to an EspeRare Foundation media release, this trial started in 4 clinical centres San Raffaele Hospital (Milano, Italy), Armand Trousseau Hospital/ I-motion (Paris, France), Great Ormond Street Hospital (London, UK) and Santa Creu i Sant Pau Hospital (Barcelona, Spain). The enrolment of 20 patients was completed in December 2017.
- 06 Feb 2018 Status changed from recruiting to completed.
- 26 Jul 2017 Planned End Date changed from 30 Mar 2017 to 1 Dec 2017.